Christopher R. Drewry

  • Partner
  • Echristopher.drewry@lw.com
  • 330 North Wabash Avenue, Suite 2800
  • Chicago, IL 60611
  • USA
  • T +1.312.777.7122
  •  
 

Profile

Christopher Drewry, a corporate partner in the Chicago office, regularly represents multinational corporations across industries and jurisdictions in their highest-stakes M&A transactions and shareholder activism defense matters.

Mr. Drewry has built a leading cross-border practice that spans the full spectrum of M&A and shareholder activism defense matters, with a focus on complex transactions and board-level advice for leading global companies. His extensive experience includes:

  • Transformational “merger of equal” and other strategic M&A transactions
  • Multijurisdictional global business separations
  • Cutting-edge shareholder activism and takeover defense counseling
  • Specialized special committee and board governance advice

Mr. Drewry regularly speaks and writes on new developments in the field, including editing the M&A chapters in the updated third edition of Investment Banking: Valuation, LBOs, M&A and IPOs and on evolving shareholder rights plan (poison pill) technologies.

He is recognized by The Legal 500 nationally as one of two next generation partners in providing advice to boards of directors on shareholder activism defense matters.

Mr. Drewry is a member of Latham’s Pro Bono Committee.

Experience

Mr. Drewry’s representative  experience includes:

Transformational Strategic M&A
  • Cerner Corporation, a leading providing of digital information services used within hospitals and health systems, in its pending $28 billion take-private sale to Oracle
  • FMC Technologies, a US-listed company, in its US$13 billion merger of equals transaction with Technip S.A., a Euronex Paris-listed designer and developer of offshore oil and gas process facilities via the EU cross-border merger regime
  • Tencent on the stock-for-stock merger of Huya and DouYu, both leading game-centric live streaming platforms
  • Sinovac Biotech in a subsidiary equity sale to Advantech Capital and Vivo Capital to accelerate COVID-19 vaccine development
  • Orbitz Worldwide, a leading global online travel company, in its US$1.6 billion take-private sale to Expedia
  • Koch Industries, Inc. in its US$7.2 billion take-private acquisition of Molex Incorporated, a leading supplier of connectors
  • Georgia-Pacific in its US$1.5 billion take-private tender offer acquisition of Buckeye Technologies, a leading manufacturer of specialty fibers and nonwoven materials
Multijurisdictional Global Business Separations
  • Colfax in its pending tax-free spinoff transaction to separate its fabrication technology and specialty medical technology businesses into two independent publicly-traded companies
  • TechnipFMC, a global oilfield services company, in its spin-off of its engineering and construction segment, forming Technip Energies
  • Delphi Automotive in its US$727 million sale of its global thermal systems business to Germanbased MAHLE GmbH
  • Aptiv (formerly Delphi Automotive) in connection with the US$4.5 billion spin-off and listing of its powertrain systems segment, forming Delphi Technologies
  • Actuant in the sale of its engineered components & systems segment to One Rock Capital Partners
Shareholder Activism and Takeover Defense
  • Kohl’s in defense a campaign by Macellum Advisors, Ancora Holdings, Legion Partners and 4010 Capital seeking board representation
  • New Relic in defense of a campaign by Engaged Capital seeking board representation and governance changes
  • Sinovac Biotech in the triggering of a shareholder rights plan against 1Globe Capital (pending)
  • Cars.com in its defense of a public campaign by Starboard Value seeking board seats
  • Zagg in defense of campaigns by Roumell Asset Management and Arex Capital Management seeking board representation
  • Spok Holdings in defense of an unsolicited offers from Acacia Research and B. Riley Financial
  • Spok Holdings in defense of a campaign by White Hat Capital seeking board representation
  • HollySys Automation in its defense of an unsolicited offer from its former CEO and CPE Fund Management Limited
  • Allison Transmission in its defense of a public campaign by Ashe Capital seeking board seats and proxy access
Special Committee and Conflict of Interest Transactions
  • The Special Committee of the Board of Directors of CNA Surety Corporation in the US$450 million take-private sale of CNA Surety to CNA Insurance
  • The Special Committee of the Board of Directors of Universal Truckload Services, Inc. (UTSI) in the US$335 million acquisition of LINC Logistics Company by UTSI
Private Equity M&A
  • Energy Capital Partners in its joint venture with ADA-ES, for a US$400 million facility producing activated carbon to control mercury emissions
  • PLH Group, a portfolio company of Energy Capital Partners, in its acquisition of four mid-stream oil and gas companies
  • GTCR in its US$446.5 million acquisition of Vocus, concurrent US$775 million acquisition of Cision and subsequent acquisition of Gorkana to form a leading global provider of PR software and services    

Thought Leadership

  • Trending Topics in Activism -  June 07, 2021
  • Considerations for REITs in Adopting a Poison Pill in Response to the COVID-19 Crisis -  June 02, 2020
  • Proactively Adopting a Poison Pill in Response to the COVID-19 Crisis -  March 30, 2020
  • M&A, Valuations and Activism: Board Lessons From 2008 -  March 20, 2020
  • Universal Proxies: What Companies Need to Know Now -  November 16, 2018
  • The Resilient Rights Plan: Recent Poison Pill Developments and Trends -  July 03, 2014
  • Ruling Offers "Poison Pill" Guidance -  May 16, 2014
  • Third Point LLC v. Ruprecht — Activism Confronts the Rights Plan -  May 14, 2014
  • The Resilient Rights Plan: Recent Poison Pill Developments and Trends -  April 2011
  • Implications of Selectica for Next-Generation Poison Pills -  March 30, 2010
  • M&A Commentary - Implications for the Next Generation of Poison Pills: Selectica, Inc. v. Versata Enterprises, Inc. -  March 23, 2010
  • Recent Poison Pill Developments and Trends -  May 12, 2009
  • The Resurgent Rights Plan: Recent Poison Pill Developments and Trends -  April 1, 2009
  • Lessons from the First Triggering of a Modern Poison Pill:
    Selectica, Inc. v. Versata Enterprises, Inc.
     -  March 2009
Recognized as a Next Generation Partner: Shareholder Activism - Advice to BoardsThe Legal 500 US, 2021
Bar Qualification
  • Illinois
Education
  • JD, Notre Dame Law School, 2007
    cum laude
  • BA, Georgetown University, 2002
    cum laude
Industries
  • Automotive
  • Energy & Infrastructure
  • Technology
Practices
  • Mergers & Acquisitions
  • Activism Defense
  • Public Company Representation
  • Private Equity
  • Corporate Governance